These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 21764706)

  • 1. [Inhibitory effect of somatostatin analogue octreotide on the expression of p53 and Ras in human gastric cancer].
    Tian L; Li S
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(7):1245-8. PubMed ID: 21764706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Inhibition of activator protein-1 on the growth of gastric cancer by octreotide].
    Wang CH; Tang CW
    Ai Zheng; 2002 Aug; 21(8):850-4. PubMed ID: 12478891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The inhibitive effects of celecoxib combined with octreotide on the metastasis of human gastric cancer in vivo].
    Huang MT; Chen ZX; Wei B; Zhang B; Wang CH; Huang MH; Tang CW
    Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(46):3255-9. PubMed ID: 17313803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relationship between expression of tumor suppressor protein p21 and p53 and cell proliferation in the gastric carcinoma].
    Huang J; Gan J
    Hunan Yi Ke Da Xue Xue Bao; 1998; 23(5):441-3. PubMed ID: 10682555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
    Stangelberger A; Schally AV; Rick FG; Varga JL; Baker B; Zarandi M; Halmos G
    Prostate; 2012 Apr; 72(5):555-65. PubMed ID: 21796649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inhibition of human gastric cancer metastasis by ocreotide in vitro and in vivo].
    Wang C; Tang C
    Zhonghua Yi Xue Za Zhi; 2002 Jan; 82(1):19-22. PubMed ID: 11953120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
    Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
    Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53, but not c-Ki-ras, mutation and down-regulation of p21WAF1/CIP1 and cyclin D1 are associated with malignant transformation in gastric hyperplastic polyps.
    Murakami K; Mitomi H; Yamashita K; Tanabe S; Saigenji K; Okayasu I
    Am J Clin Pathol; 2001 Feb; 115(2):224-34. PubMed ID: 11211611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of combined octreotide and aspirin on the growth of gastric cancer.
    Tang C; Wang C; Tang L
    Chin Med J (Engl); 2003 Mar; 116(3):373-7. PubMed ID: 12781040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of COX-2 and K-ras expression to clinical outcome in gastric cancer.
    Li M; Liu W; Zhu YF; Chen YL; Zhang BZ; Wang R
    Acta Oncol; 2006; 45(8):1115-9. PubMed ID: 17118848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients.
    van der Hoek J; van der Lelij AJ; Feelders RA; de Herder WW; Uitterlinden P; Poon KW; Boerlin V; Lewis I; Krahnke T; Hofland LJ; Lamberts SW
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):176-84. PubMed ID: 16060911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer.
    Kamoshida S; Suzuki M; Shimomura R; Sakurai Y; Komori Y; Uyama I; Tsutsumi Y
    Br J Cancer; 2007 Jan; 96(2):277-83. PubMed ID: 17211470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between the long-term effects of intraperitoneal chemotherapy and the expression of p53 and p21 in patients with gastric carcinoma at stage IIIa and stage IIIb.
    Ikeguchi M; Saito H; Katano K; Gomyo Y; Tsujitani S; Maeta M; Kaibara N
    Int Surg; 1997; 82(2):170-4. PubMed ID: 9331847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation.
    Drebber U; Baldus SE; Nolden B; Grass G; Bollschweiler E; Dienes HP; Hölscher AH; Mönig SP
    Oncol Rep; 2008 Jun; 19(6):1477-83. PubMed ID: 18497953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. K-ras mutations in gastric stump carcinomas and in carcinomas from the non-operated stomach.
    van Rees BP; Musler A; Caspers E; Drillenburg P; Craanen ME; Polkowski W; Chibowski D; Offerhaus GJ
    Hepatogastroenterology; 1999; 46(27):2063-8. PubMed ID: 10430398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of expression of p21 and p53 proteins and proliferating cell nuclear antigen in pancreatic cancer.
    Dang CX; Han Y; Qin ZY; Wang YJ
    Hepatobiliary Pancreat Dis Int; 2002 May; 1(2):302-5. PubMed ID: 14612290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression and significance of cell cycle regulators in gastric carcinoma].
    Wu JF; Shao JC; Wang DB; Qin R; Zhang H
    Ai Zheng; 2005 Feb; 24(2):175-9. PubMed ID: 15694028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical detection of RAS, JUN, FOS, and p53 oncoprotein expression in human colorectal adenomas and carcinomas.
    Magrisso IJ; Richmond RE; Carter JH; Pross CB; Gilfillen RA; Carter HW
    Lab Invest; 1993 Dec; 69(6):674-81. PubMed ID: 8264230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular markers in gastric cancer: can p53 and bcl-2 protein expressions be used as prognostic factors?
    Zafirellis K; Karameris A; Milingos N; Androulakis G
    Anticancer Res; 2005; 25(5):3629-36. PubMed ID: 16101192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutated p53 protein expression and proliferative activity in advanced gastric cancer.
    Ikeguchi M; Saito H; Kondo A; Tsujitani S; Maeta M; Kaibara N
    Hepatogastroenterology; 1999; 46(28):2648-53. PubMed ID: 10522058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.